INNOCARE (09969) has announced its interim results for 2026, reporting total revenue of approximately RMB 1.137 billion, representing a year-on-year increase of 55.46%. The company achieved an adjusted profit of approximately RMB 277 million, marking a turnaround from a loss in the prior corresponding period. Profit attributable to owners of the parent company reached approximately RMB 246 million, also reflecting a shift to profitability on a year-on-year basis.

The revenue growth was primarily driven by robust increases in drug sales revenue, alongside milestone deliveries resulting from the collaboration with Zenas BioPharma, Inc. (NASDAQ: ZBIO). Drug sales climbed 43.2% from RMB 641 million in the six months ended June 30, 2025, to RMB 918 million, propelled mainly by the sustained strong performance of Orelabrutinib and the new market launches of Tafasitamab and Zolbetuximab.

During the reporting period, INNOCARE further advanced its multi-product, multi-therapeutic-area strategy, with expanding contributions across hematological malignancies, autoimmune diseases, and solid tumors. Multiple assets have either approached or achieved key regulatory and clinical milestones, laying a solid foundation for sustained long-term growth.

With several products now commercialized or nearing regulatory submission, INNOCARE has entered a new phase of diversified growth, enhancing earnings predictability while broadening its global business footprint. Leveraging disciplined execution and portfolio expansion, the company is well-positioned to create sustainable value over time.